Spero Therapeutics

Spero Therapeutics

A biopharmaceutical company that develops treatments for multi-drug resistant (MDR) bacterial infection

Spero Therapeutics is a privately owned clinical-stage biopharmaceutical company headquartered in Cambridge Massachusetts. The company focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections.

Products

SPR994

Spero's lead product candidate is SPR994, which is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections, especially complicated urinary tract infections (cUTI). The treatment is derived from tebipenem, an antibiotic produced by Meiji Seika Pharma in Japan, which is used to treat common pediatric infections including pneumonia, otitis media, and sinusitis.

SPR741

Spero is also pursuing a couple of product candidates through its IV Potentiator Platform. SPR741 is an IV product that when combined with an antibiotic, has demonstrated the ability to expand the spectrum and potency of the co-administered antibiotic against Gram-negative bacteria.

SPR206

It has completed Phase 1A and 1B clinical trials highlighting its tolerability and pharmacokinetic profile. SPR206 is an IV direct-acting antibiotic that has shown activity against Acinetobacter baumanii and Pseudomonas aeruginosa in preclinical studies. It has completed non-clinical, IND enabling studies supporting its advancement as a clinical candidate to treat MDR and extensively drug-resistant (XDR) bacterial strains.

SPR720

Spero has another product candidate, SPR720, in very early stages. It is an oral therapy designed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. In November 2018, the company announced positive results from its IND-enabling studies and intends to initiate Phase 1 clinical trials in early 2019.

Timeline

March 2017

Spero Therapeutics raises a $51,700,000 series C round from GV, Rock Springs Capital and RA Capital Management.

2013

Spero Therapeutics was founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Ankit Mahadevia

President & CEO

Carol Waldo

Head of Regulatory Affairs

Christina Larkin

COO

David Melnick

Chief Medical Officer

Ian A. Critchley

Head of Clinical Microbiology

Jay Blackington

Head of People Strategy and Culture

Joel Sendek

CFO

Melissa Stundick

Executive Director of Strategic Alliances

Michael Pucci

Executive Director - Early Drug Discovery

Steve Garbacz

Senior VP of Finance and Operations

Susannah Walpole

Head of Clinical Operations

Thomas Parr

Chief Scientific Officer

Timothy Keutzer

Senior VP of Development

Troy Lister

VP of Research

Further reading

Title
Author
Link
Type
Date

Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial

Spero Therapeutics, Inc.

Web

Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720

Spero Therapeutics, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.